Payment overview · 2025
General Payments
$3,900.88
59 reported records · 20 companies
Healthcare provider profile · identity verified
Dimitrios Virvilis, MD
Allopathic & Osteopathic Physicians|Surgery|Vascular Surgery · COLUMBIA, SC · NPI 1275795148
Verified facts
What the public records show
CMS Open Payments records show Dimitrios Virvilis, MD received $3,900.88 in general payments during 2025 across 59 reported records.
Penumbra, Inc. accounted for 35.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 36 associated products.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Penumbra, Inc. | Unresolved — no canonical attribution shown | $1,372.34 | 35.2% | 3 | 2025 |
| W. L. Gore & Associates, Inc. | Unresolved — no canonical attribution shown | $643.46 | 16.5% | 10 | 2025 |
| Integra LifeSciences Corporation | Unresolved — no canonical attribution shown | $497.93 | 12.8% | 8 | 2025 |
| Tactile Systems Technology Inc | Unresolved — no canonical attribution shown | $271.21 | 7.0% | 8 | 2025 |
| CVRx, Inc. | Unresolved — no canonical attribution shown | $237.11 | 6.1% | 2 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $148.42 | 3.8% | 7 | 2025 |
| Shape Memory Medical Inc. | Unresolved — no canonical attribution shown | $142.67 | 3.7% | 1 | 2025 |
| Smith+Nephew, Inc. | Unresolved — no canonical attribution shown | $102.83 | 2.6% | 3 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$100.97 | 2.6% | 5 | 2025 |
| Surmodics, Inc. | Unresolved — no canonical attribution shown | $77.25 | 2.0% | 1 | 2025 |
| 180 Medical, Inc. | Unresolved — no canonical attribution shown | $54.59 | 1.4% | 2 | 2025 |
| Cagent Vascular INC | Unresolved — no canonical attribution shown | $50.00 | 1.3% | 1 | 2025 |
| Solventum Corporation | Unresolved — no canonical attribution shown | $39.95 | 1.0% | 1 | 2025 |
| Access Pro Medical, LLC | Unresolved — no canonical attribution shown | $34.44 | 0.9% | 1 | 2025 |
| Bard Peripheral Vascular, Inc. | Unresolved — no canonical attribution shown | $27.44 | 0.7% | 1 | 2025 |
| AngioDynamics, Inc. | Unresolved — no canonical attribution shown | $25.90 | 0.7% | 1 | 2025 |
| Flowphysix Inc | Unresolved — no canonical attribution shown | $22.42 | 0.6% | 1 | 2025 |
| Imperative Care, Inc | Unresolved — no canonical attribution shown | $20.08 | 0.5% | 1 | 2025 |
| Chiesi USA, Inc. | Unresolved — no canonical attribution shown | $16.58 | 0.4% | 1 | 2025 |
| Organogenesis Inc. | Unresolved — no canonical attribution shown | $15.29 | 0.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,771.18 | 53 |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $1,200.00 | 1 |
| Travel and Lodging | $535.11 | 4 |
| Long term medical supply or device loan | $394.59 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Indigo System Normalized: indigo system |
Device | Penumbra, Inc. | $1,372.34 | 3 | 2025 |
Source payment records
|
|||||
| GORE EXCLUDER Thoracoabdominal Branch Endoprosthesis Normalized: gore excluder thoracoabdominal branch endoprosthesis |
Device | W. L. Gore & Associates, Inc. | $620.11 | 9 | 2025 |
Source payment records
|
|||||
| Cytal Normalized: cytal |
Device | Integra LifeSciences Corporation | $394.59 | 1 | 2025 |
Source payment records
|
|||||
| Flexitouch Plus Normalized: flexitouch plus |
Device | Tactile Systems Technology Inc | $271.21 | 8 | 2025 |
Source payment records
|
|||||
| Nimbl Normalized: nimbl |
Device | Tactile Systems Technology Inc | $271.21 | 8 | 2025 |
Source payment records
|
|||||
| Barostim Neo System Normalized: barostim neo system |
Device | CVRx, Inc. | $237.11 | 2 | 2025 |
Source payment records
|
|||||
| IMPEDE EMBOLIZATION PLUG Normalized: impede embolization plug |
Device | Shape Memory Medical Inc. | $142.67 | 1 | 2025 |
Source payment records
|
|||||
| Integra Normalized: integra |
Device | Integra LifeSciences Corporation | $103.34 | 7 | 2025 |
Source payment records
|
|||||
| Integra Dermal Regeneration Template Normalized: integra dermal regeneration template |
Device | Integra LifeSciences Corporation | $103.34 | 7 | 2025 |
Source payment records
|
|||||
| PRIMATRIX Normalized: primatrix |
Device | Integra LifeSciences Corporation | $103.34 | 7 | 2025 |
Source payment records
|
|||||
| COLLAGENASE SANTYL Normalized: collagenase santyl |
Drug | Smith+Nephew, Inc. | $102.83 | 3 | 2025 |
Source payment records
|
|||||
| Pounce LP Thrombectomy Normalized: pounce lp thrombectomy |
Device | Surmodics, Inc. | $77.25 | 1 | 2025 |
Source payment records
|
|||||
| Pounce Thrombectomy Normalized: pounce thrombectomy |
Device | Surmodics, Inc. | $77.25 | 1 | 2025 |
Source payment records
|
|||||
| Pounce Thrombectomy System Normalized: pounce thrombectomy system |
Device | Surmodics, Inc. | $77.25 | 1 | 2025 |
Source payment records
|
|||||
| Pounce Venous Thrombectomy System Normalized: pounce venous thrombectomy system |
Device | Surmodics, Inc. | $77.25 | 1 | 2025 |
Source payment records
|
|||||
| Pounce XL Thrombectomy Normalized: pounce xl thrombectomy |
Device | Surmodics, Inc. | $77.25 | 1 | 2025 |
Source payment records
|
|||||
| Ranger Normalized: ranger |
Device | Boston Scientific Corporation | $57.55 | 1 | 2025 |
Source payment records
|
|||||
| IN.PACT ADMIRAL Normalized: in pact admiral |
Device | Medtronic, Inc. | $55.94 | 3 | 2025 |
Source payment records
|
|||||
| Serrantor Normalized: serrantor |
Device | Cagent Vascular INC | $50.00 | 1 | 2025 |
Source payment records
|
|||||
| ELUVIA Normalized: eluvia |
Device | Boston Scientific Corporation | $49.43 | 1 | 2025 |
Source payment records
|
|||||
| ACTIV.A.C. Normalized: activ a c |
Device | Solventum Corporation | $39.95 | 1 | 2025 |
Source payment records
|
|||||
| MATRIDERM Normalized: matriderm |
Device | Access Pro Medical, LLC | $34.44 | 1 | 2025 |
Source payment records
|
|||||
| JUZO BASIC Normalized: juzo basic |
Medical Supply | 180 Medical, Inc. | $29.67 | 1 | 2025 |
Source payment records
|
|||||
| Denali Vena Cava Filter Normalized: denali vena cava filter |
Device | Bard Peripheral Vascular, Inc. | $27.44 | 1 | 2025 |
Source payment records
|
|||||
| ANGIOVAC Normalized: angiovac |
Device | AngioDynamics, Inc. | $25.90 | 1 | 2025 |
Source payment records
|
|||||
| MEDI Normalized: medi |
Medical Supply | 180 Medical, Inc. | $24.92 | 1 | 2025 |
Source payment records
|
|||||
| CLOSUREFAST Normalized: closurefast |
Device | Medtronic, Inc. | $23.81 | 1 | 2025 |
Source payment records
|
|||||
| GORE VIABAHN VBX Balloon Expandable Endo Normalized: gore viabahn vbx balloon expandable endo |
Device | W. L. Gore & Associates, Inc. | $23.35 | 1 | 2025 |
Source payment records
|
|||||
| FLOWRUNNER Normalized: flowrunner |
Device | Flowphysix Inc | $22.42 | 1 | 2025 |
Source payment records
|
|||||
| ENDURANT IIS Normalized: endurant iis |
Device | Medtronic, Inc. | $21.22 | 1 | 2025 |
Source payment records
|
|||||
| SYMPHONY CATHETER Normalized: symphony catheter |
Device | Imperative Care, Inc | $20.08 | 1 | 2025 |
Source payment records
|
|||||
| ENROUTE Transcarotid Neuroprotection System Normalized: enroute transcarotid neuroprotection system |
Device | Boston Scientific Corporation | $17.56 | 2 | 2025 |
Source payment records
|
|||||
| CLEVIPREX Normalized: cleviprex |
Drug | Chiesi USA, Inc. | $16.58 | 1 | 2025 |
Source payment records
|
|||||
| APLIGRAF Normalized: apligraf |
Device | Organogenesis Inc. | $15.29 | 1 | 2025 |
Source payment records
|
|||||
| ENROUTE Enflate Transcarotid RX Balloon Dilatation Catheter Normalized: enroute enflate transcarotid rx balloon dilatation catheter |
Device | Boston Scientific Corporation | $13.30 | 1 | 2025 |
Source payment records
|
|||||
| ENROUTE Transcarotid Stent Normalized: enroute transcarotid stent |
Device | Boston Scientific Corporation | $10.58 | 2 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
No publishable same-company prescribing overlap was found in the loaded Part D year. This does not mean the doctor never prescribed a drug reported elsewhere by a paying company.
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Clopidogrel | Clopidogrel Bisulfate | 19 | suppressed |
| Xarelto | Rivaroxaban | 13 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $3,900.88 · 59 records | Penumbra, Inc. | ACTIV.A.C., ANGIOVAC, APLIGRAF, Barostim Neo System, CLEVIPREX, CLOSUREFAST, COLLAGENASE SANTYL, Cytal, Denali Vena Cava Filter, ELUVIA, ENDURANT IIS, ENROUTE Enflate Transcarotid RX Balloon Dilatation Catheter, ENROUTE Transcarotid Neuroprotection System, ENROUTE Transcarotid Stent, FLOWRUNNER, Flexitouch Plus, GORE EXCLUDER Thoracoabdominal Branch Endoprosthesis, GORE VIABAHN VBX Balloon Expandable Endo, IMPEDE EMBOLIZATION PLUG, IN.PACT ADMIRAL, Indigo System, Integra, Integra Dermal Regeneration Template, JUZO BASIC, MATRIDERM, MEDI, Nimbl, PRIMATRIX, Pounce LP Thrombectomy, Pounce Thrombectomy, Pounce Thrombectomy System, Pounce Venous Thrombectomy System, Pounce XL Thrombectomy, Ranger, SYMPHONY CATHETER, Serrantor | — | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error